The U.S. Department of Health and Human Services (HHS) has announced that the ordering process for monoclonal antibody drugs has transitioned from the direct ordering process to a state-coordinated distribution system, similar to the process previously used from November 2020 to February 2021.
Effective immediately, administration sites no longer order directly from AmerisourceBergen. Weekly distribution amounts for each state/territory will be determined by HHS based on weekly reports of new COVID-19 cases and hospitalizations in addition to data on inventories and use submitted in HHSProtect, and state/territorial health departments will determine where the product is distributed in their jurisdictions.
The change in ordering and distribution is made in response to recent significant surges in the use of monoclonal antibodies, resulting from increased incidence of the Delta variant of SARS-CoV-2, particularly in areas with low vaccination rates.
Additional information is available on the HHS website.